LEXINGTON, Mass., April 4,
2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer, today announced that
James Dentzer, President and Chief
Executive Officer of Curis, will participate at the 23rd
Annual Needham Virtual Healthcare Conference being held on
April 8 - 11, 2024.
Presentation details are as follows:
- Format: Company Presentation
- Date: Monday, April 8, 2024
- Time: 12:45 PM ET
A live webcast and archived replay will be available and can be
accessed here or on the Events & Presentations section of
Curis's website.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study in patients with relapsed/refractory primary
central nervous system lymphoma (PCNSL) in combination with the BTK
inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim
Leukemia study in patients with relapsed/refractory acute myeloid
leukemia (AML) and relapsed/refractory high risk myelodysplastic
syndrome (hrMDS), both of which have received Orphan Drug
Designation from the U.S. Food and Drug Administration. Emavusertib
is also being evaluated as a frontline combination therapy with
azacitidine and venetoclax in patents with AML. Curis, through its
2015 collaboration with Aurigene, has the exclusive license to
emavusertib (CA-4948). Curis licensed its rights to Erivedge® to
Genentech, a member of the Roche Group, under which they are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website at
www.curis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-april-302108020.html
SOURCE Curis, Inc.